DK0915701T3 - Hurtigoplöselige galanthaminhydrobromidtabletter - Google Patents

Hurtigoplöselige galanthaminhydrobromidtabletter

Info

Publication number
DK0915701T3
DK0915701T3 DK97927159T DK97927159T DK0915701T3 DK 0915701 T3 DK0915701 T3 DK 0915701T3 DK 97927159 T DK97927159 T DK 97927159T DK 97927159 T DK97927159 T DK 97927159T DK 0915701 T3 DK0915701 T3 DK 0915701T3
Authority
DK
Denmark
Prior art keywords
rapidly soluble
galanthamine hydrobromide
hydrobromide tablets
tablets
galanthamine
Prior art date
Application number
DK97927159T
Other languages
Danish (da)
English (en)
Inventor
Paul Marie Victor Gilis
Conde Valentin Florent Vict De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0915701T3 publication Critical patent/DK0915701T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97927159T 1996-06-14 1997-06-06 Hurtigoplöselige galanthaminhydrobromidtabletter DK0915701T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201676 1996-06-14
EP97927159A EP0915701B1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet

Publications (1)

Publication Number Publication Date
DK0915701T3 true DK0915701T3 (da) 2005-04-25

Family

ID=8224084

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97927159T DK0915701T3 (da) 1996-06-14 1997-06-06 Hurtigoplöselige galanthaminhydrobromidtabletter

Country Status (33)

Country Link
US (2) US6099863A (pl)
EP (1) EP0915701B1 (pl)
JP (1) JP4172820B2 (pl)
KR (1) KR100358676B1 (pl)
CN (1) CN1102390C (pl)
AR (2) AR008237A1 (pl)
AT (1) ATE285777T1 (pl)
AU (1) AU726212B2 (pl)
BG (1) BG64168B1 (pl)
BR (1) BR9709729A (pl)
CA (1) CA2257431C (pl)
CZ (1) CZ295226B6 (pl)
DE (1) DE69732113T2 (pl)
DK (1) DK0915701T3 (pl)
EA (1) EA001193B1 (pl)
EE (1) EE03337B1 (pl)
ES (1) ES2235234T3 (pl)
HK (1) HK1019703A1 (pl)
HR (1) HRP970321B1 (pl)
ID (1) ID17088A (pl)
IL (1) IL127519A (pl)
MY (1) MY121669A (pl)
NO (1) NO322892B1 (pl)
NZ (1) NZ333280A (pl)
PL (1) PL189329B1 (pl)
PT (1) PT915701E (pl)
SI (1) SI0915701T1 (pl)
SK (1) SK284620B6 (pl)
TR (1) TR199802592T2 (pl)
TW (1) TW506836B (pl)
UA (1) UA62930C2 (pl)
WO (1) WO1997047304A1 (pl)
ZA (1) ZA975281B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
ES2211215T3 (es) * 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
PT1578422E (pt) 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
US7465465B2 (en) * 2003-08-26 2008-12-16 Shire Biochem Inc. Pharmaceutical formulation comprising lanthanum compounds
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051489A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
ES2519690T3 (es) * 2004-09-24 2014-11-07 University Of Maryland, Baltimore Método de tratamiento de envenenamiento por organosfósforo
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (es) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US8168219B2 (en) * 2005-11-30 2012-05-01 Isp Investments Inc. Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
PL2010158T3 (pl) * 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
US20100152108A1 (en) 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2116232B1 (de) 2008-05-09 2012-02-15 Ratiopharm GmbH Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
CN106822008A (zh) * 2017-01-11 2017-06-13 江苏艾兰得营养品有限公司 一种维生素d速溶制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ATE183084T1 (de) * 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
CN1102390C (zh) 2003-03-05
BR9709729A (pt) 1999-08-10
NO985815L (no) 1998-12-11
JP2000511918A (ja) 2000-09-12
BG64168B1 (bg) 2004-03-31
AU726212B2 (en) 2000-11-02
SI0915701T1 (en) 2005-06-30
AR008237A1 (es) 1999-12-29
SK284620B6 (sk) 2005-07-01
CZ295226B6 (cs) 2005-06-15
DE69732113D1 (de) 2005-02-03
CN1222077A (zh) 1999-07-07
PL189329B1 (pl) 2005-07-29
ID17088A (id) 1997-12-04
NO985815D0 (no) 1998-12-11
HK1019703A1 (en) 2000-02-25
JP4172820B2 (ja) 2008-10-29
SK169698A3 (en) 1999-10-08
NZ333280A (en) 1999-09-29
AR070670A2 (es) 2010-04-28
EP0915701A1 (en) 1999-05-19
WO1997047304A1 (en) 1997-12-18
PT915701E (pt) 2005-05-31
CA2257431A1 (en) 1997-12-18
ATE285777T1 (de) 2005-01-15
HRP970321A2 (en) 1998-04-30
ZA975281B (en) 1998-12-14
DE69732113T2 (de) 2005-12-08
MY121669A (en) 2006-02-28
CZ403498A3 (cs) 1999-03-17
US6358527B1 (en) 2002-03-19
HRP970321B1 (en) 2001-12-31
EE03337B1 (et) 2001-02-15
UA62930C2 (uk) 2004-01-15
AU3174397A (en) 1998-01-07
CA2257431C (en) 2001-11-20
EA001193B1 (ru) 2000-12-25
ES2235234T3 (es) 2005-07-01
IL127519A (en) 2002-07-25
US6099863A (en) 2000-08-08
EA199900026A1 (ru) 1999-06-24
TR199802592T2 (xx) 1999-03-22
EP0915701B1 (en) 2004-12-29
PL330431A1 (en) 1999-05-10
NO322892B1 (no) 2006-12-18
TW506836B (en) 2002-10-21
IL127519A0 (en) 1999-10-28
KR20000015851A (ko) 2000-03-15
KR100358676B1 (ko) 2003-02-17
BG102991A (en) 1999-08-31

Similar Documents

Publication Publication Date Title
DK0915701T3 (da) Hurtigoplöselige galanthaminhydrobromidtabletter
DE69737936D1 (de) Arzneimittel
PT942718E (pt) Comprimidos de maleato de trimebutina revestidos
DK0818140T3 (da) Blokfremstillingsindretning
DE59703450D1 (de) Tablettenprüfgerät
DE69601919T2 (de) Filtrierapparat
DE29621865U1 (de) Portions-Tablette
NO983259L (no) Famciclovir tabletter
DE9308071U1 (de) Höhenverstellbare Toilettenanordnung
HUP9903476A3 (en) Fast-dissolving galanthamine hydrobromide tablet
DE29618094U1 (de) Pharmazeutisches Präparat
ATA77096A (de) Pharmazeutische präparation
DE29600830U1 (de) Dichtungsbahn
DE29618897U1 (de) Sanitärschutzvorrichtung
ES1027529Y (es) Base de enchufe perfeccionada.
UA1330S (uk) Глибинна кільцева марка
KR970053768U (ko) 정
BR9601135A (pt) Pastilhas de acerola
SE9500250D0 (sv) Portionstabletter
UA1246S (uk) Таблетка фармацевтична
LV10417A (lv) Plaksnisu kede
KR960027059U (ko) 차류
NO962396D0 (no) Fundament
UA634S (uk) Чайний набір
BR7600905U (pt) Similar bingo horizontal